No OS Boost With Opdivo in Recurrent Glioblastoma

Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.

Go to full article published by MedPage Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.